Tenon Medical Raises $4.3 Million in Private Placement

An announcement from Tenon Medical, Inc. ( (TNON) ) is now available.

On March 11, 2026, Tenon Medical, Inc. entered into securities purchase agreements for a private placement of senior convertible promissory notes and on March 12, 2026, announced the closing of the transaction, raising gross proceeds of $4.3 million from institutional and high net worth investors. The 20% original issue discount notes carry an aggregate principal amount of $4.3 million, mature on September 11, 2026, and become convertible six months after issuance into common stock at 80% of the volume-weighted average price over the three trading days before conversion.

The financing, conducted as an exempt private offering under U.S. securities laws, includes provisions for a possible maturity extension with a principal increase and requires partial prepayment from future securities financings. Tenon expects to deploy the net proceeds toward commercial expansion of its sacroiliac joint fusion platform, product development, clinical studies, working capital and general corporate purposes, potentially strengthening its growth trajectory and competitive position in the SI joint device market.

The most recent analyst rating on (TNON) stock is a Hold with a $0.75 price target. To see the full list of analyst forecasts on Tenon Medical, Inc. stock, see the TNON Stock Forecast page.

Spark’s Take on TNON Stock

According to Spark, TipRanks’ AI Analyst, TNON is a Neutral.

The score is held back most by persistent large losses and ongoing cash burn, despite improving revenue and gross margins and a healthier, low-debt balance sheet. Technicals remain bearish with the stock below major moving averages. The latest earnings call and financing activity are constructive for growth and liquidity, but profitability and self-funding are not yet in sight.

To see Spark’s full report on TNON stock, click here.

More about Tenon Medical, Inc.

Tenon Medical, Inc., founded in 2012 and listed on Nasdaq under the symbol TNON, is a medical device company focused on transforming care for patients with sacro-pelvic disorders. Its flagship product is the Catamaran SI Joint Fusion System, a less invasive sacroiliac joint fusion platform using a single titanium implant for primary SI procedures, revisions of failed implants and augmentation of spinal fusions.

The Catamaran Fixation Device crosses both the axial and sagittal planes of the ilium and sacrum to stabilize the SI joint along its longitudinal axis while targeting stronger cortical bone and avoiding critical neural and vascular structures. Following the U.S. national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon has concentrated on commercial expansion within the SI joint market across primary, revision and adjunct fusion indications.

Average Trading Volume: 1,039,288

Technical Sentiment Signal: Sell

Current Market Cap: $9.65M

Find detailed analytics on TNON stock on TipRanks’ Stock Analysis page.